Company intelligence / Profile preview

SelfDecode

Miami, Florida, USA

Ownership: Private
Employees: ~60
Development stage: Commercial

Overview

SelfDecode offers a commercial direct-to-consumer platform that analyzes over 200 million genetic variants to provide users with comprehensive DNA-based health reports. The company integrates genetics with lab results and lifestyle data to deliver actionable recommendations. It has developed proprietary ancestry-adjusted polygenic risk scoring algorithms and provides both consumer-facing products and B2B licensing of its bioinformatics infrastructure. Over 650 detailed trait/health reports are available; the company also supports clinicians through a Pro plan.

Therapeutic areas: OtherCardiovascularRare Diseases
Modalities: Non-pharmacological therapyDevice
Industry: Molecular Diagnostics

Partnerships

No major pharma/biotech partnerships publicly listed as of June 2025.

Beyond the preview

Go deeper on SelfDecode.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SelfDecode.

Explore the full profile